Mar 06, 2020
European Commission Grants AbbVie Marketing Authorization Shortening MAVIRET® (glecaprevir/pibrentasvir) Treatment Duration to Eight Weeks for Treatment-Naïve Chronic HCV Patients with Genotype 3 and Compensated Cirrhosis
Mar 05, 2020
Zydus Announces World's First Drug for the Treatment of Non-Cirrhotic NASH
Mar 05, 2020
Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2019 Financial Results and Provide Business Update on Thursday March 12
Mar 03, 2020
DURECT Corporation Announces Fourth Quarter and Full Year 2019 Financial Results and Update of Programs
Feb 25, 2020
Clinical Study Supports Bergacyn® for Liver and Vascular Health
Feb 19, 2020
ChemomAb Ltd. Announces Issuance of Composition of Matter Patent for CM-101 and Reinforces its IP Portfolio
Feb 17, 2020
Ascletis' IND Filing for Its Non-alcoholic Steatohepatitis (NASH) Drug Accepted by NMPA
Feb 12, 2020
Liminal BioSciences Announces Scientific Presentations at Upcoming Keystone Symposia
Feb 12, 2020
Antios Therapeutics Initiates First-in-Human Phase I Study of ATI-2173
Feb 06, 2020
ProSciento and Nordic Bioscience Form Strategic Partnership to Develop Translational Biomarkers for Nonalcoholic Steatohepatitis (NASH)
Jan 30, 2020
Novel Coronavirus: In Vitro Diagnostics Brought to Bear
Jan 28, 2020
Enzychem Lifesciences Appoints Dr. Michael Charlton To Its Scientific Advisory Board
Jan 22, 2020
Ascletis Received Approval of Clinical Trials in HBV Patients for ASC22, a Subcutaneously Administered PD-L1 Antibody
Jan 22, 2020
Metacrine Demonstrates Best-in-Class FXR Drug Program with Positive Clinical Results in NASH Patients
Jan 13, 2020
Akero Therapeutics Expands Phase 2a Trial in NASH to Include Cohort of Cirrhotic Patients
Dec 16, 2019
Akero Therapeutics Completes Enrollment in Phase 2a Study in NASH
Dec 10, 2019
Liver Health Supplements Market Size Worth $948.61 Million by 2025: Grand View Research, Inc.
Nov 21, 2019
Enzychem Lifesciences Presents EC-18 NASH Development Update at The Liver Meeting 2019
Nov 19, 2019
Viking Therapeutics Announces Initiation of Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
Nov 13, 2019
J. Craig Venter Institute and UC San Diego Develop Phage Treatment as Potential Cure for Alcoholic Liver Disease